Fig. 2.

Small molecular inhibitors enhancing viral infection. a Analyses of LTR-driven EGFP expression reveal that a large proportion of compounds present in library (49%) have greater than +0.5 log₂ fold change in viral infection. b 17 compounds with greater than +0.5 log₂ fold-change in EGFP targeted the HDAC family of enzymes, presented with percent infection compared to the no drug control (ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001) and with viability data. c Six non-HDAC compounds also demonstrated greater than +0.5 log₂ fold-change in EGFP and targeted the L3MBTL3 methyl-lysine binging protein, cellular hydroxylases, and bromodomain proteins. For both b and c, the infection and viability data correspond to the drug concentrations with the largest effect on infection with ≥70% viability compared to the no drug control. Compounds in gray with greater than +0.5 log₂ fold change demonstrated cytotoxicity (viability ≤70%)